
[Figure 8]

Analysis results of His-Tag-purified protein by LC-MS/MS




[Figure 11]


Measurement of affinity of Trastuzumab scFv with HER2 extracellular domain by Biacore X100


Immobilized side; HER2ex.
Flow channel side; scFv

Single cycle method



Multi-cycle method






[Figure 12]

Measurement of affinity of Trastuzumab full-body antibody with HER2 extracellular domain by Biacore X100

Single cycle method


0.05% Tween20-PBS

Trastuzumab full-body Ab



$KD=3.56x10^{-9}$ [M]
$ka=1.87x10^{4}$ [1/Ms]
$kd=6.65x10^{-5}$ [1/s]


Trastuzumab scFv



$KD=1.52x10^{-10}$ [M]
$ka=1.03x10^{6}$ [1/Ms]
$kd=1.57x10^{-4}$ [1/s]

[Figure 13]


FACS analysis of binding ability of Trastuzumab scFv and Trastuzumab full-body antibody to human breast cancer cell lines



*Trastuzumab scFv and anti-CMVpp65 scFv Ab at 10ug/ml, Trastuzumab full-body Ab (neat supernatant of Sf9 cells)

**MDA-MB-231(HER2-) SKBR-3 (HER2++)

[Figure 19]



[Figure 20]

